Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
John FanikosJoshua Norkin GoldsteinBelinda LovelaceAnne C BeaubrunRobert S BlissettFilipa AragãoPublished in: Journal of medical economics (2022)
Given these results, the use of andexanet alfa for the reversal of anticoagulation in patients with factor Xa inhibitor-related ICH may improve quality of life and is likely to be cost-effective in a US context.